Clinical Trials on Botryoid-Type Embryonal Rhabdomyosarcoma

Total 7808 results

Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.

Active, not recruiting

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

Melanoma

Italy
Mayo Clinic

Active, not recruiting

Education for Prevention of Melanoma in Hispanic Populations

Melanoma

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Melanoma

United States
University of Virginia

Completed

Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma (Mel54)

Melanoma

United States
Bristol-Myers Squibb

Completed

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

Melanoma

Brazil, Chile, United States, Ireland, Italy, Spain, Argentina, Australia, Canada, France, Mexico, New Zealand, Poland, Romania
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)

Melanoma

United States
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
NYU Langone Health

Active, not recruiting

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Fondazione Melanoma Onlus

Withdrawn

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Melanoma

Italy
John Kirkwood
Bristol-Myers Squibb

Active, not recruiting

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Melanoma

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC; Novartis

Active, not recruiting

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma (Neo Trio)

Melanoma

Australia
Georgetown University
Exelixis; Hackensack Meridian Health; MedStar Franklin Square Medical Center

Suspended

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Completed

Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Melanoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Genentech, Inc.

Completed

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Melanoma

United States
University Hospital, Essen

Active, not recruiting

Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma

Melanoma

Germany
Royal Free Hospital NHS Foundation Trust
Merck Sharp & Dohme LLC; University College, London

Completed

Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab (PASIP)

Melanoma | Neoplasms

United Kingdom
Novartis Pharmaceuticals

Completed

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Melanoma

United States
University of Pennsylvania

Active, not recruiting

Dendritic Cell Vaccination in Patients With Advanced Melanoma

Melanoma

United States
Nova Scotia Health Authority

Terminated

Melanoma Accuracy Study; Phase 2

Melanoma

Canada
Ludwig Institute for Cancer Research
Austin Health; Peter MacCallum Cancer Institute

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma

Melanoma

Australia
Ludwig Institute for Cancer Research
Institute of Cancer Research, United Kingdom

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Melanoma

United Kingdom, Australia, New Zealand
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Celgene Corporation

Completed

Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma

Melanoma

United States
M.D. Anderson Cancer Center

Terminated

Sample Collection From Melanoma Patients

Melanoma

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Active, not recruiting

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Melanoma

United States
Istari Oncology, Inc.
Duke University

Completed

PVSRIPO for Patients With Unresectable Melanoma

Melanoma

United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Melanoma

Australia, United States
University of Utah
Bristol-Myers Squibb; Takara Bio Inc.

Terminated

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Melanoma

United States
Bristol-Myers Squibb

Withdrawn

Yervoy Pregnancy Surveillance Study

Melanoma

United States
Hellenic Cooperative Oncology Group

Active, not recruiting

Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications

Melanoma

Greece
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma

Melanoma

Japan
Fondazione Melanoma Onlus

Completed

Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation (VEMUPLINT)

Melanoma

Italy
Bristol-Myers Squibb

Completed

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

Melanoma

United States
MacroGenics
Massachusetts General Hospital

Terminated

Tissue Procurement Substudy for Participants in Study CP-MGA271-01

Melanoma

United States
Michael Weichenthal

Terminated

PTK/ZK in Disseminated Malignant Melanoma

Melanoma

Germany
Radboud University Medical Center

Completed

myDC/pDC in Stage III Melanoma Patients

Melanoma

Netherlands
Bristol-Myers Squibb

Active, not recruiting

A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed

Melanoma

Belgium, Luxembourg
M.D. Anderson Cancer Center

Completed

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

Melanoma

United States
Bristol-Myers Squibb

Completed

Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (CheckMate 401)

Melanoma

Australia, France, Italy, Belgium, Finland, Austria, Ireland, Sweden, Switzerland, United Kingdom, Germany, Norway
Northwestern University
Sarah M. Friedewald, MD; Jennifer N. Choi, MD

Completed

Skin Self-Examination Education During Mammography (SSE)

Melanoma

United States
Novartis Pharmaceuticals

Completed

Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

Melanoma

United States
Novartis Pharmaceuticals

Completed

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Melanoma

Canada, Spain, United Kingdom, Netherlands, United States, Argentina, Australia, France, Germany, Greece, Italy, Russian Federation, Sweden, Ukraine
University of California, San Francisco
Merck Sharp & Dohme LLC; OncoSec Medical Incorporated

Completed

Trial of pIL-12/MK-3475 in Metastatic Melanoma

Melanoma

United States
Bristol-Myers Squibb

Completed

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

Melanoma

Italy, France, Spain, Australia
GlaxoSmithKline

Completed

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma (PREDICT)

Melanoma

United States, Spain, Germany, France, Poland, Italy, Ireland, Russian Federation
Cambridge University Hospitals NHS Foundation Trust
University of Oxford; National Institute for Health Research, United Kingdom; Oxford University Hospitals NHS Trust

Completed

Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma (INTERIM)

Melanoma

United Kingdom
University of Warmia and Mazury
National Center for Research and Development, Poland; Medical University of... and other collaborators

Unknown

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

Neuroendocrine Tumors

Poland
Loyola University
National Cancer Institute (NCI)

Active, not recruiting

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Melanoma

United States
National Cancer Institute (NCI)

Completed

Sun Exposure and Melanoma in Agricultural Workers

Melanoma

United States
Philip Friedlander
Genentech, Inc.

Terminated

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Melanoma

United States
M.D. Anderson Cancer Center
Schering-Plough

Completed

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Melanoma

United States

Clinical Trials on Botryoid-Type Embryonal Rhabdomyosarcoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations